✦ LIBER ✦

O1-131 * PHASE III STUDY OF CRIZOTINIB VS. CHEMOTHERAPY IN ADVANCED ALK+ NSCLC: PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE

✍ Scribed by Nokihara, H.; Hirsh, V.; Blackhall, F.; Kim, D.- W.; Besse, B.; Han, J.- Y.; Wilner, K.; Reisman, A.; Iyer, S.; Shaw, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ERCC1, toxicity and quality of life in a

✍ Adam Vilmar; Eric Santoni-Rugiu; Jens Benn Sørensen 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 225 KB

32 LUX-Lung 3: Symptom and health-relate

✍ O'Byrne, K.J.; Sequist, L.V.; Schuler, M.; Yamamoto, N.; Hirsh, V.; Mok, T.; Lun 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A multicenter, randomized phase III stud

✍ Belani, C.P; Rodriguez, J; von Pawel, J; Pluzanska, A; Gorbounova, V; Millward, 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 98 KB

Docetaxel + Cisplatin (DC) and Docetaxel

✍ F. Fossella 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 140 KB